An Observational Study Assessing the Clinical Effectiveness of VeriStrat and Validating Immunotherapy Tests in Subjects With Non-Small Cell Lung Cancer
The purpose of this study is to collect information about how a doctor uses the results of the VeriStrat® blood test to guide treatment for non-small cell lung cancer (NSCLC) patients. Understanding how VeriStrat test results influence doctors' decisions and patients' outcomes may help doctors to better treat NSCLC in the future. This study will also look to establish whether new investigational tests can help better predict the effectiveness of certain medications for certain patients. These new investigational tests are only for research purposes at this time.
• Subject must be 18 years of age or older at time of signing informed consent form (ICF).
• A diagnosis of NSCLC.
• Subject is willing to provide serum samples for VeriStrat testing.
• EGFR mutation status wild-type (negative) or a tested unknown.
• For subjects with untested/unknown EGFR status only: The subject must be willing to provide blood samples for GeneStrat testing.
• Subject is willing to provide serum samples for research, understanding that no test results will be made available either to the subject or the treating physician.
• Subject is able to read and understand the ICF and agrees to comply with study procedures and requirements.